Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLD and LD Consolidation/Maintenance in Multiple Myeloma Post-Transplant
NCT02353468Phase 2Terminated
- Sponsor
- University of Colorado Denver
- Start
- Dec 2009
- Primary completion
- Oct 2011
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by University of Colorado Denver. Primary endpoint: Event Free Survival at 5 years. Started Dec 2009; status: terminated.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02353468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353468.